Genetics of pulmonary arterial hypertension

Clinics in Chest Medicine

Volumn 34, Issue 4, 2013, Pages 651-663

  Elliott, C Gregory ^a,b  

^a INTERMOUNTAIN MEDICAL CENTER   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Activin like kinase receptor; Bone morphogenetic protein receptor; Caveolin; Endoglin; Genetics; Pulmonary arterial hypertension; SMAD9; Voltage gated potassium channel

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; ANOREXIGENIC AGENT; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; CALCIUM ACTIVATED POTASSIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CAVEOLIN 1; ENDOGLIN;

ALK1 GENE; AUTOSOMAL DOMINANT INHERITANCE; BMPR2 GENE; CAV1 GENE; CONNECTIVE TISSUE DISEASE; DISEASE ASSOCIATION; DNA SEQUENCE; ENG GENE; GENE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC CODE; GENETIC COUNSELING; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HUMAN; KCNK3 GENE; LUNG CIRCULATION; MUTATIONAL ANALYSIS; NONSENSE MUTATION; ONSET AGE; PEDIGREE ANALYSIS; PHARMACOGENETICS; PORTAL HYPERTENSION; PREVALENCE; PRIORITY JOURNAL; PULMONARY CAPILLARY HEMANGIOMATOSIS; PULMONARY HYPERTENSION; PULMONARY VENO-OCCLUSIVE DISEASE; REVIEW; SMAD9 GENE; SURVIVAL RATE; SYSTEMIC PULMONARY SHUNT; VIRUS INFECTION;

ACTIVIN-LIKE KINASE RECEPTOR; BONE MORPHOGENETIC PROTEIN RECEPTOR; CAVEOLIN; ENDOGLIN; GENETICS; PULMONARY ARTERIAL HYPERTENSION; SMAD9; VOLTAGE GATED POTASSIUM CHANNEL;

AGE OF ONSET; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; CHROMOSOMES, HUMAN, PAIR 2; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MUTATION; PEDIGREE;

EID: 84888166865     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2013.08.003     Document Type: Review

References (80)

1. Rubin L.J. Primary pulmonary hypertension. Chest 1993, 104(1):236-250.
2. McLaughlin V.V., Archer S.L., Badesch D.B., et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009, 119(16):2250-2294.
3. Badesch D.B., Champion H.C., Gomez Sanchez M.A., et al. Diagnosis and assessment of pulmonary arterial hypertension. JAm Coll Cardiol 2009, 54(Suppl 1):S55-S66.
4. Badesch D.B., Abman S.H., Ahearn G.S., et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004, 126(Suppl 1):35S-62S.
5. Barst R.J., Gibbs J.S., Ghofrani H.A., et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. JAm Coll Cardiol 2009, 54(Suppl 1):S78-S84.
6. Rich S., Kaufmann E., Levy P.S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. NEngl J Med 1992, 327(2):76-81.
7. Sitbon O., Humbert M., Jais X., et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005, 111(23):3105-3111.
8. Simonneau G., Robbins I.M., Beghetti M., et al. Updated clinical classification of pulmonary hypertension. JAm Coll Cardiol 2009, 54(Suppl 1):S43-S54.
9. Deng Z., Morse J.H., Slager S.L., et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000, 67(3):737-744.
10. Lane K.B., Machado R.D., Pauciulo M.W., et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet 2000, 26(1):81-84.
11. Trembath R.C., Thomson J.R., Machado R.D., et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. NEngl J Med 2001, 345(5):325-334.
12. Dresdale D.T., Michtom R.J., Schultz M. Recent studies in primary pulmonary hypertension, including pharmacodynamic observations on pulmonary vascular resistance. Bull N Y Acad Med 1954, 30(3):195-207.
13. Loyd J.E., Primm R.K., Newman J.H. Familial primary pulmonary hypertension: clinical patterns. Am Rev Respir Dis 1984, 129(1):194-197.
14. Larkin E.K., Newman J.H., Austin E.D., et al. Longitudinal analysis casts doubt on the presence of genetic anticipation in heritable pulmonary arterial hypertension. Am J Respir Crit Care Med 2012, 186(9):892-896.
15. Loyd J., Butler M., Foroud T., et al. Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension. Am J Respir Crit Care Med 1995, 152(1):93-97.
16. Newman J.H., Loyd J.E. Familial pulmonary hypertension. The pulmonary circulation: normal and abnormal 1990, 301-313. University of Pennsylvania Press, Philadelphia. A.P. Fishman (Ed.).
17. Elliott C.G., Alexander G., Leppert M., et al. Coancestry in apparently sporadic primary pulmonary hypertension. Chest 1995, 108:973-977.
18. Newman J.H., Wheeler L., Lane K.B., et al. Mutation in the gene for bone morphogenetic protein receptor ii as a cause of primary pulmonary hypertension in a large kindred. NEngl J Med 2001, 345(5):319-324.
19. Nichols W.C., Koller D.L., Slovis B., et al. Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32. Nat Genet 1997, 15(3):277-280.
20. Morse J.H., Jones A.C., Barst R.J., et al. Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31-q32. Circulation 1997, 95(12):2603-2606.
21. De Caestecker M., Meyrick B. Bone morphogenetic proteins, genetics and the pathophysiology of primary pulmonary hypertension. Respir Res 2001, 2(4):193-197.
22. Machado R.D., Eickelberg O., Elliott C.G., et al. Genetics and genomics of pulmonary arterial hypertension. JAm Coll Cardiol 2009, 54(Suppl 1):S32-S42.
23. Thomson J.R., Machado R.D., Pauciulo M.W., et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. JMed Genet 2000, 37(10):741-745.
24. Machado R.D., Pauciulo M.W., Thomson J.R., et al. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 2001, 68(1):92-102.
25. Aldred M.A., Vijayakrishnan J., James V., et al. BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension. Hum Mutat 2006, 27(2):212-213.
26. Machado R.D., Aldred M.A., James V., et al. Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat 2006, 27(2):121-132.
27. Cogan J.D., Vnencak-Jones C.L., Phillips J.A., et al. Gross BMPR2 gene rearrangements constitute a new cause for primary pulmonary hypertension. Genet Med 2005, 7(3):169-174.
28. Cogan J.D., Pauciulo M.W., Batchman A.P., et al. High frequency of BMPR2 exonic deletions/duplications in familial pulmonary arterial hypertension. Am J Respir Crit Care Med 2006, 174(5):590-598.
29. Aldred M.A., Machado R.D., James V., et al. Characterization of the BMPR2 5'-untranslated region and a novel mutation in pulmonary hypertension. Am J Respir Crit Care Med 2007, 176(8):819-824.
30. Humbert M., Morrell N.W., Archer S.L., et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. JAm Coll Cardiol 2004, 43(12 Suppl S):13S-24S.
31. Li W., Dunmore B.J., Morrell N.W. Bone morphogenetic protein type II receptor mutations causing protein misfolding in heritable pulmonary arterial hypertension. Proc Am Thorac Soc 2010, 7(6):395-398.
32. West J., Niswender K.D., Johnson J.A., et al. Apotential role for insulin resistance in experimental pulmonary hypertension. Eur Respir J 2013, 41(4):861-871.
33. Girerd B., Montani D., Eyries M., et al. Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension. Respir Res 2010, 11:73.
34. Sztrymf B., Coulet F., Girerd B., et al. Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. Am J Respir Crit Care Med 2008, 177(12):1377-1383.
35. Pfarr N., Szamalek-Hoegel J., Fischer C., et al. Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutations. Respir Res 2011, 12:99.
36. Elliott C.G., Glissmeyer E.W., Havlena G.T., et al. Relationship of BMPR2 mutations to vasoreactivity in pulmonary arterial hypertension. Circulation 2006, 113(21):2509-2515.
37. Rosenzweig E.B., Morse J.H., Knowles J.A., et al. Clinical implications of determining BMPR2 mutation status in a large cohort of children and adults with pulmonary arterial hypertension. JHeart Lung Transplant 2008, 27(6):668-674.
38. Austin E.D., Phillips J.A., Cogan J.D., et al. Truncating and missense BMPR2 mutations differentially affect the severity of heritable pulmonary arterial hypertension. Respir Res 2009, 10:87.
39. Attisano L., Carcamo J., Ventura F., et al. Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors. Cell 1993, 75(4):671-680.
40. Wu X., Robinson C.E., Fong H.W., et al. Cloning and characterization of the murine activin receptor like kinase-1 (ALK-1) homolog. Biochem Biophys Res Commun 1995, 216(1):78-83.
41. Favaro JP, Wiley K, Blobe GC. Alk1. UCSD-Nature Molecule Pages. 2005. http://dx.doi.org/10.1038/mp.a000254.000201.
42. ten Dijke P., Yamashita H., Ichijo H., et al. Characterization of type I receptors for transforming growth factor-beta and activin. Science 1994, 264(5155):101-104.
43. Abdalla S.A., Letarte M. Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease. JMed Genet 2006, 43(2):97-110.
44. Harrison R.E., Berger R., Haworth S.G., et al. Transforming growth factor-beta receptor mutations and pulmonary arterial hypertension in childhood. Circulation 2005, 111(4):435-441.
45. Girerd B., Montani D., Coulet F., et al. Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. Am J Respir Crit Care Med 2010, 181(8):851-861.
46. Harrison R.E., Flanagan J.A., Sankelo M., et al. Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia. JMed Genet 2003, 40(12):865-871.
47. Chaouat A., Coulet F., Favre C., et al. Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension. Thorax 2004, 59(5):446-448.
48. Llorca O., Trujillo A., Blanco F.J., et al. Structural model of human endoglin, a transmembrane receptor responsible for hereditary hemorrhagic telangiectasia. JMol Biol 2007, 365(3):694-705.
49. Ray B, Blobe GC. Endoglin. UCSD-Nature Molecule Pages. 2005. http://dx.doi.org/10.1038/mp.a000048.000001.
50. Shovlin C.L. Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev 2010, 24(6):203-219.
51. Shintani M., Yagi H., Nakayama T., et al. Anew nonsense mutation of SMAD8 associated with pulmonary arterial hypertension. JMed Genet 2009, 46(5):331-337.
52. Chida A., Shintani M., Nakayama T., et al. Missense mutations of the BMPR1B (ALK6) gene in childhood idiopathic pulmonary arterial hypertension. Circ J 2012, 76(6):1501-1508.
53. Yang X., Long L., Southwood M., et al. Dysfunctional smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. Circ Res 2005, 96(10):1053-1063.
54. Austin E.D., Ma L., LeDuc C., et al. Whole exome sequencing to identify a novel gene (caveolin-1) associated with human pulmonary arterial hypertension. Circ Cardiovasc Genet 2012, 5(3):336-343.
55. Razani B., Zhang X.L., Bitzer M., et al. Caveolin-1 regulates transforming growth factor (TGF)-beta/SMAD signaling through an interaction with the TGF-beta type I receptor. JBiol Chem 2001, 276(9):6727-6738.
56. Maniatis N.A., Shinin V., Schraufnagel D.E., et al. Increased pulmonary vascular resistance and defective pulmonary artery filling in caveolin-1-/- mice. Am J Physiol Lung Cell Mol Physiol 2008, 294(5):L865-L873.
57. Ma L., Roman-Campos D., Austin E.D., et al. A novel channelopathy in pulmonary arterial hypertension. N Engl J Med 2013, 369:351-361.
58. Mandegar M., Yuan J.X. Role of K+ channels in pulmonary hypertension. Vascul Pharmacol 2002, 38(1):25-33.
59. Germain M., Eyries M., Montani D., et al. Genome-wide association analysis identifies a susceptibility locus for pulmonary arterial hypertension. Nat Genet 2013, 45(5):518-521.
60. Rich S., Dantzker D.R., Ayres S.M., et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987, 107(2):216-223.
61. Humbert M., Sitbon O., Chaouat A., et al. Pulmonary arterial hypertension in France: results from a National Registry. Am J Respir Crit Care Med 2006, 173(9):1023-1030.
62. Badesch D.B., Raskob G.E., Elliott C.G., et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010, 137(2):376-387.
63. Humbert M., Deng Z., Simonneau G., et al. BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives. Eur Respir J 2002, 20(3):518-523.
64. Roberts K.E., McElroy J.J., Wong W.P., et al. BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease. Eur Respir J 2004, 24(3):371-374.
65. Morse J., Barst R., Horn E., et al. Pulmonary hypertension in scleroderma spectrum of disease: lack of bone morphogenetic protein receptor 2 mutations. JRheumatol 2002, 29(11):2379-2381.
66. Tew M.B., Arnett F.C., Reveille J.D., et al. Mutations of bone morphogenetic protein receptor type II are not found in patients with pulmonary hypertension and underlying connective tissue diseases. Arthritis Rheum 2002, 46(10):2829-2830.
67. Nunes H., Humbert M., Sitbon O., et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2003, 167(10):1433-1439.
68. Roberts K.E., Fallon M.B., Krowka M.J., et al. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med 2009, 179(9):835-842.
69. Montani D., Price L.C., Dorfmuller P., et al. Pulmonary veno-occlusive disease. Eur Respir J 2009, 33(1):189-200.
70. Voordes C.G., Kuipers J.R., Elema J.D. Familial pulmonary veno-occlusive disease: a case report. Thorax 1977, 32(6):763-766.
71. Montani D., Achouh L., Dorfmuller P., et al. Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine (Baltimore) 2008, 87(4):220-233.
72. Runo J.R., Vnencak-Jones C.L., Prince M., et al. Pulmonary veno-occlusive disease caused by an inherited mutation in bone morphogenetic protein receptor II. Am J Respir Crit Care Med 2003, 167(6):889-894.
73. Wagenvoort C.A., Beetstra A., Spijker J. Capillary haemangiomatosis of the lungs. Histopathology 1978, 2(6):401-406.
74. Langleben D., Heneghan J.M., Batten A.P., et al. Familial pulmonary capillary hemangiomatosis resulting in primary pulmonary hypertension. Ann Intern Med Jul 15 1988, 109(2):106-109.
75. Best D.H., Sumner K.L., Austin E.D., et al. EIF2AK4 mutations in pulmonary capillary hemangiomatosis. CHEST 2013, [Epub ahead of print].
76. Badesch D.B., Abman S.H., Simonneau G., et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007, 131(6):1917-1928.
77. Frydman N., Steffann J., Girerd B., et al. Pre-implantation genetic diagnosis in pulmonary arterial hypertension due to BMPR2 mutation. Eur Respir J 2012, 39(6):1534-1535.
78. An act to prohibit discrimination on the basis of genetic information with respect to health insurance and employment: Wikipedia, 2008; Public Law enacted by the 110th United States Congress. Available at. Accessed October 10, 2013. http://en.wikipedia.org/wiki/Genetic_Information_Nondiscrimination_Act.
79. Maitland-van der Zee A.H., de Boer A., Leufkens H.G. The interface between pharmacoepidemiology andpharmacogenetics. Eur J Pharmacol 2000, 410(2-3):121-130.
80. Murali S. Pulmonary arterial hypertension. Curr Opin Crit Care 2006, 12(3):228-234.